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Abstract
Aberrant DNA methylation observed in cancer can provide survival beneﬁts to cells by silencing genes essential for
anti-tumor activity. DNA-demethylating agents such as Decitabine (DAC)/Azacitidine (AZA) activate otherwise silenced
tumor suppressor genes, alter immune response and epigenetically reprogram tumor cells. In this study, we show that
non-cytotoxic nanomolar DAC concentrations modify the bladder cancer transcriptome to activate NOTCH1 at the
mRNA and protein level, increase double-stranded RNA sensors and CK5-dependent differentiation. Importantly, DAC
treatment increases ICN1 expression (the active intracellular domain of NOTCH1) signiﬁcantly inhibiting cell
proliferation and causing changes in cell size inducing morphological alterations reminiscent of senescence. These
changes were not associated with β-galactosidase activity or increased p16 levels, but instead were associated with
substantial IL-6 release. Increased IL-6 release was observed in both DAC-treated and ICN1 overexpressing cells as
compared to control cells. Exogenous IL-6 expression was associated with a similar enlarged cell morphology that was
rescued by the addition of a monoclonal antibody against IL-6. Treatment with DAC, overexpression with ICN1 or
addition of exogenous IL-6 showed CK5 reduction, a surrogate marker of differentiation. Overall this study suggests
that in MIBC cells, DNA hypomethylation increases NOTCH1 expression and IL-6 release to induce CK5-related
differentiation.
Introduction
The ﬁve-year survival of patients with invasive bladder
cancer who present with locally advanced or metastatic
disease is less than 25%1. Neoadjuvant cisplatin-based
chemotherapy (CBC) followed by radical cystectomy
remains the ﬁrst line treatment for muscle-invasive blad-
der cancer (MIBC) patients over the last three decades.
Although CBC is associated with a survival advantage,
inherent and acquired cisplatin resistance is frequently
observed1 and associated with survival rates of <2 years2.
Agents targeting DNA methylation such as 5-aza-2’-
deoxycytidine (Decitabine, DAC) and 5-azacytidine
(Azacytidine, AZA) are FDA-approved for the treatment
of myelodysplastic syndrome3. These agents, in part,
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decrease DNA hypermethylation of CG-rich regions (CpG
islands) in promoters of tumor suppressor genes and
restore transcriptional activity of those loci4,5. DNA-
demethylating agents (1) induce immune responses6,7, (2)
reprogram tumors by targeting self-renewing cell popu-
lation8,9 and (3) sensitize tumors to chemotherapy or
immunotherapy based upon checkpoint inhibition6,10.
Targeting DNA methylation in tumors presents a unique
opportunity to alter cell transcriptional programs, activate
tumor suppressors and immune system regulating genes
to achieve therapeutic beneﬁt, either alone or in combi-
nation with other anticancer therapies.
NOTCH1 expression can be lost through non-sense
mutations in MIBC tumors11. We hypothesized that
NOTCH1 expression is also lost due to DNA hyper-
methylation of its promoter region and subsequent tran-
scriptional repression. Mice with an inactive NOTCH
pathway have a greater incidence of carcinogen-induced
bladder tumor with squamous features and reduced
overall survival12. NOTCH1 expression and its down-
stream targets JAGGED-1 and HES-1 are also lost in
aggressive forms of MIBC13,14. NOTCH1 activation sen-
sitizes osteosarcoma cells to cisplatin treatment15. One
potential downstream target of NOTCH1 signaling is IL-
6, a pro-inﬂammatory cytokine associated with poor
prognosis in patients with different types of solid tumors
through activation of the JAK/STAT pathway16,17.
NOTCH1 has been shown to locate to the IL-6 promoter
to increase its expression18. IL-6 release in the context of
DNA damage-induced senescence is considered to be
pro-tumorigenic19,20. However in bladder cancer, IL-6
overexpression reduces motility and invasion in vitro in
MIBC cells with IL-6 knockdown increasing tumor bur-
den in vivo21. Our study shows for the ﬁrst time that DAC
restores NOTCH1 expression and promotes IL-6 medi-
ated CK5-differentiation in muscle-invasive bladder can-
cer cells.
Results
Non-cytotoxic decitabine concentrations induce DNA
hypomethylation of the NOTCH1 promoter leading to
NOTCH1 transcriptional activation
DAC is used for treatment in patients with acute mye-
locytic leukemia and myelodysplastic syndrome. In these
patients, standard DAC therapy generally results in
plasma levels in the range of 50nM–1 µM when measured
1–2 h after receiving DAC (15–20mg/m2 of I.V infu-
sion)22,23. Because DAC is given intravenously, plasma
concentrations are not representative of those in solid
tissues. For patients receiving DAC for the treatment of
solid tumors, the actual levels which reach the target
tumor tissue are likely to be signiﬁcantly lower. To mimic
concentrations that are therapeutically relevant, in our
in vitro experiments, we used 0.1 and 1 µM DAC. We
analyzed: (1) HT1376 and T24 cell lines of epithelial
origin with p53 inactivating mutations and (2) B01 and
B0224,25 patient-derived xenograft cells with squamous
differentiation and wild-type p53. Both 0.1 and 1 µMDAC
successfully depleted DNA methyltransferase 1 (DNMT1)
(Supplementary Fig. 1a), and signiﬁcantly reduced LINE-1
methylation by 10–20% in T24 and B02 cells (Supple-
mentary Fig. 1b). Although LINE-1 methylation was clo-
ser to 10% or less in untreated HT1376 and B01 cells,
DAC treatment reduced LINE-1 methylation levels by 2%
in these cells (Supplementary Fig. 1b). These results
conﬁrm that low nanomolar DAC doses are active in all
the cell lines tested. Both 0.1 and 1 µM DAC signiﬁcantly
reduced cell proliferation by greater than 50% without
affecting viability in more than 20% of the cells compared
to the vehicle (Fig. 1a, Supplementary Fig. 1c). DAC also
lowered the ability of cells to form individual subclones
compared to control cells (Fig. 1b, c). To delineate the
transcriptional mechanisms by which non-cytotoxic DAC
doses reduced cell proliferation we used paired-end RNA-
sequencing. We used DAC-treated T24 cells with sig-
niﬁcant decrease in LINE-1 methylation (Supplementary
Fig. 1b) for these analyses. RNA sequencing revealed that
166 genes and 350 genes were upregulated in 0.1 and 1
µM DAC-treated T24 cells, respectively, compared to
control cells. Interestingly gene enrichment analysis of
differentially expressed genes in DAC-treated cells
revealed upregulation of the NOTCH pathway (Supple-
mentary Figure 2a and Supplementary Table 1). We
conﬁrmed our RNA sequencing results by qPCR and
found more than two-fold increase in the NOTCH1
transcript in all cell lines (Fig. 1d). The increase in
NOTCH1 transcript was signiﬁcant in HT1376, T24, and
B01 cells with an upward trend observed in B02 cells
(Fig. 1d). This led us to investigate whether NOTCH1-
signaling is clinically important in bladder cancer. RNA-
sequencing and survival data from Roswell Park Cancer
Institute (RPCI) MIBC patients showed that NOTCH1
upregulation (z-score threshold of +1.5) correlated with
greater overall survival and progression-free survival
compared with patients with no alterations in NOTCH1
expression (Supplementary Fig. 2b). We used the TCGA
bladder cancer database to conﬁrm these ﬁndings. We
found NOTCH1 transcript and protein upregulation (z-
score threshold of +1.5) in 11–12% of patient samples
(Supplementary Fig. 2c). These patients exhibited better
overall (OS) and progression-free survival (PFS) com-
pared to patients with no alterations in NOTCH1
expression (Supplementary Fig. 2c). NOTCH1 was
methylated in a subset of bladder tumors in both the RPCI
and TCGA cohorts (Supplementary Table 3 and Supple-
mentary Fig. 2d). A subset of tumors with methylation β-
values >0.3 corresponded with low NOTCH1 mRNA
levels (z-scores <1). Therefore, we investigated whether
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Fig. 1 DNA hypomethylation increases NOTCH1 expression and alters cell size. Bladder tumor cells were treated with DAC every 48 h for up to
5 days. a 0.1 and 1 µM DAC caused a reduction in cell proliferation in all four bladder tumor cell lines. The Y axis represents percentage changes in cell
counts in DAC-treated cells as compared to control cells. Error bars indicate standard error of means from triplicate experiments and technical
duplicates in each experiment. b, c DAC treatment reduced the number of clones in bladder tumor cells lines. The number of clones were counted
and compared to control cells. The Y axis represents the number of clones in control and treatment conditions. Error bars indicate standard error of
means from triplicate experiments and technical duplicates. d DAC induced NOTCH1 transcript in bladder tumor cell lines. The Y axis represents fold
change in DAC-treated cells as compared to control cells. Error bars indicate standard error of means from triplicate experiments and technical
duplicates in each experiment. e, f DAC treatment decreased DNA methylation at the NOTCH1 promoter and enhancer regions. The Y-axis represents
percentage DNA methylation with error bars indicating standard error of means from duplicate experiments and technical duplicates in each
experiment. g, h Western blot analysis of DAC-treated bladder tumor cells showed an increase in the active intracellular domain of NOTCH1 (ICN1) in
HT1376 and T24 but not in B01 and B02. GAPDH was used as the loading control. The western blot is a representative of triplicate experiments. i
Western blot analysis of B01 and B02 cells cultured in DMEM showed an increase in levels of the active intracellular domain of NOTCH1, ICN1. GAPDH
was used as the loading control. The western blot is a representative of triplicate experiments. j Bright ﬁeld images of Giemsa staining showed
morphological changes in DAC-treated cells. DAC-treated cells appeared enlarged and ﬂattened as compared to control cells on Day 5. The images
are representative of duplicate experiments. ________ represents 10 µm. k The horizontal length of 50 cells from each condition was measured by
ImageJ. The graph represents an average measurement of 50 cells in control, and DAC-treated groups. The DAC-treated cells were signiﬁcantly larger
as compared to the control cells. Student’s t-test was used to compare control and treated cells in all the panels. *p < 0.05, **p < 0.01.
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DNA methylation regulates NOTCH1 expression or
activation in bladder cancer cells. NOTCH1 promoter and
enhancer regions are hypermethylated (above 70%) in all
four cell lines (Fig. 1e–f). DAC demethylated both the
promoter and enhancer regions to below 50%; this cor-
related with increased NOTCH1 transcript (Fig. 1e–f).
DAC-treated HT1376 and T24 cells have greater ICN1
protein expression, the active transmembrane domain of
NOTCH1, compared to control cells (Fig. 1g). These
results show for the ﬁrst time that DNA methylation
contributes to the transcriptional regulation of NOTCH1
expression in bladder cancer cells.
B01 and B02 cells are cultured in media containing
cholera toxin which degrades NOTCH1 and ICN1
Fig. 2 IL-6 is a downstream mediator of DAC-induced morphological alterations in an NOTCH1 dependent and independent manner. a
ICN1 transient overexpression increased IL-6 release in cell supernatants at 72 h. The Y axis indicates IL-6 in pg/ml normalized for 1 × 106 cells from
triplicate experiments and technical duplicates with error bars indicating standard error of means. b Bladder tumor cells were treated with DAC every
48 h for up to 5 days. DAC caused IL-6 release in bladder tumor cell lines with a robust increase in HT1376 cells. The Y-axis indicates IL-6 in pg/ml
normalized for 1 × 106 cells from triplicate experiments and technical duplicates with error bars indicating standard error of means. c–e mRNA levels
of double-stranded RNA sensors increased in DAC-treated cells. The Y-axis indicates average fold change over control cells from triplicate
experiments and technical duplicates with error bars indicating standard error of means. Student’s t-test was used to compare control and treated
cells. *p < 0.05, **p < 0.01. f Bright ﬁeld images of Giemsa staining showed morphological changes in cells with exogenous IL-6. Cells with exogenous
IL-6 appeared enlarged and ﬂattened as compared to control cells. The addition of IL-6 monoclonal antibody reduced the appearance of DAC-
induced enlarged cell morphology. _________ represents 10 µm. g The addition of a monoclonal antibody against IL-6 with DAC treatment
inhibited IL-6 release as compared to DAC treatment alone. The Y-axis indicates IL-6 in pg/ml normalized for 1 × 106 cells from triplicate experiments
and technical duplicates with error bars indicating standard error of means. h The horizontal length of 50 cells from each condition was measured by
ImageJ. The graph represents an average measurement of 50 cells in control and treated groups. Student’s t-test was used to compare control and
treated cells. *p < 0.05, **p < 0.01.
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protein26 (Fig. 1h). To conﬁrm this, we used short-term
cultures of B01 and B02 in regular DMEM media without
cholera toxin. DAC-treated B01 and B02 cells cultured in
DMEM had higher ICN1 expression as compared to
control cells (Fig. 1i). For the remainder of the study, we
used B01 and B02 cells cultured in specialized F12K/
DMEM media: (1) to avoid selective pressure on B01 and
B02 cells by culturing them in regular DMEM media and
(2) to investigate NOTCH independent anti-proliferative
mechanisms of DAC treatment.
DAC and NOTCH1 mediate IL-6 release and morphological
changes in MIBC cells
Giemsa staining revealed that DAC-treated cells
underwent morphological changes compared to
untreated cells (Fig. 1j, k). Except T24 cells, DAC-treated
HT1376, B01, and B02 cells appeared enlarged compared
to controls (Fig. 1j, k). We used ﬂow cytometry to con-
ﬁrm this morphological change, where we observed
increase in channel number which corresponds to higher
voltage and therefore greater cell size in DAC-treated
cells compared to control cells (Supplementary Fig. 1d,
e). To analyze whether morphological alterations were
driven in part by NOTCH1 activation, we transiently
overexpressed ICN1 in HT1376, T24 and B01/B02 cells
cultured in DMEM. ICN1 overexpression reduced cell
proliferation with cells appearing enlarged compared to
control cells (Supplementary Fig. 3a, b). These mor-
phological changes were reminiscent of a senescent
phenotype27,28. Therefore, DAC-treated cells and ICN1
overexpressing cells were tested for β-gal staining and
p16 expression to identify if DAC and/or NOTCH1
activation causes senescence. Only a fraction of DAC-
treated T24 and B01 cells stained positively for β-gal
(Supplementary Fig. 3e). Since β-gal staining was high in
untreated HT1376, it was not possible to determine if
DAC treatment caused an increase in β-gal staining
(Supplementary Fig. 3e). There was no observable
increase in β-gal staining in DAC-treated B02 cells
(Supplementary Fig. 3e). DAC-induced p16 only in
HT1376 cells and was not detectable in the other three
cell lines (Supplementary Fig. 3f). 0.1 µM DAC
treatment-induced p27 expression in HT1376 and B02
cells (Supplementary Fig. 3g). Although we did not
measure c-myc a downstream target of p279, another
study has shown that nanomolar DAC concentrations
reduce c-myc expression29. ICN1 overexpressing cells
had a low number of β-gal positive cells and no p16
induction as compared to control cells (Supplementary
Fig. 3c, d). IL-6 release in the media was used as an
additional measure of senescence-associated secretory
phenotype in both DAC-treated and ICN1 over-
expressing cells. ICN1 overexpressing cells had higher
IL-6 in cell supernatants (greater than 200 pg/ml/106
cells) compared to control cells (Fig. 2a). DAC-treated
HT1376 cells also maintained high IL-6 release (greater
than 2000pg/ml/106 cells) compared to DAC-treated
T24, B01 and B02 cells (Fig. 2b). NOTCH1 is a known
upstream regulator of IL-6 signaling18,30. It is possible
that greater IL-6 release in HT1376 cells was due to
DAC-induced ICN1 expression, though IL-6 release was
also observed in B01 and B02 cells cultured in enriched
media where ICN1 protein expression was not detected
(Fig. 2b). IL-6 release can be triggered by the presence of
double-stranded RNAs31,32. DAC treatment has been
shown to upregulate a viral defense pathway through an
increase in double-stranded RNAs in colorectal and
ovarian cancer cell lines6,7. DAC concentrations in the
µM range also activate the IFN-γ pathway in p53 mutant
mouse embryonic ﬁbroblasts (MEFs)33. In bladder can-
cer cells, DAC treatment increased the double-stranded
RNA sensors, MDA5, MAVS and RIG-1 (Fig. 2c–e),
intermediate mediator IRF7, and downstream targets
IFI44 and IFI27 and IFN-γ by 2-fold to 70-fold compared
to control cells (Supplementary Fig. 4a–d). HT1376 cells
exhibited 10–20 fold induction of downstream targets
IFI27 and IFI44 compared to 5-fold to 10-fold change
T24, B01 and B02 cells (Supplementary Fig. 4c, d). These
data suggest that DAC treatment can also increase IL-6
levels by upregulating double-stranded RNAs. The
massive amount of IL-6 release observed with DAC
treatment and ICN1 overexpression does not explain
and is disproportionate to the small number of β-gal
positive cells. Senescence-associated IL-6 secretion is
usually associated with DNA damage19,20. DAC did not
induce γH2A.X associated DNA damage in HT1376, T24
and B01 cell lines but increased γH2A.X expression in
B02 cells (Supplementary Fig. 4e, f). The low levels of β-
gal positivity (Supplementary Fig. 3c, e), negative p16
expression (Supplementary Fig. 3d, f), p27 induction
(Supplementary Fig. 3g) and the increase in γH2A.X
observed only in B02 cells (Supplementary Fig. 4e, f)
indicate that it is unlikely that IL-6 release is related to
senescence in this case.
IL-6 mediates morphological changes and CK5-related
differentiation in DAC-treated bladder cancer cells
To test if DAC-mediated IL-6 release activates down-
stream IL-6 signaling, we measured phospho-STAT3
levels, a well-established readout of the IL-6 signaling
cascade34. p-STAT3 and STAT3 protein levels did not
increase by greater than two-fold in DAC-treated cells
(Supplementary Figure 5a), and p-STAT3 and STAT3
levels were depleted 24 h after DAC addition (Supple-
mentary Figure 5b). Our data suggests that IL-6 release
occurs without sustained activation of the JAK/STAT
pathway. Therefore, we tested if IL-6 is a mediator of
morphological alterations in DAC-treated cells.
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Exogenous IL-6 addition led to enlarged cell morphology
(Fig. 2f, h). Increase in p-STAT3 levels 30 min after IL-6
addition showed that exogenous IL-6 is active in cells
(Supplementary Fig. 5c). Exogenous IL-6 and monoclonal
antibody against IL-6 did not cause signiﬁcant change in
cell proliferation alone or in combination with DAC
(Supplementary Fig. 4g). The addition of a monoclonal
antibody against IL-6 in DAC-treated cells reduced the
appearance of enlarged cells in comparison to DAC
treatment alone (Fig. 2f–h). We hypothesized that mor-
phological alterations are indicative of differentiation8,35.
CK5 positive basal stem-like cells are thought to be the
progenitors of carcinoma in situ, muscle-invasive and
squamous cell carcinoma lesions36. Therefore, we used
the loss of CK5 protein expression as a surrogate marker
of differentiation in DAC-treated and ICN1 over-
expressing cells. DAC treatment reduced CK5 protein
expression suggesting that these cells are losing the
population of cells that can increase tumorigenic potential
(Fig. 3a, b). Transient ICN1 overexpression down-
regulated CK5 protein expression (Fig. 3c, d) suggesting
that these cells are also undergoing CK5-related differ-
entiation. Exogenous IL-6 reduced CK5 protein levels in
HT1376 and B02 cells (Fig. 3e, f). Monoclonal antibody
against IL-6 suppressed DAC-mediated IL-6 release and
rescued the CK5 expression in DAC-treated HT1376 and
B02 cells (Fig. 3e, f). These results suggest that IL-6 is a
mediator of CK5-related differentiation in MIBC cells.
Fig. 3 IL-6 and NOTCH1 are mediators of CK5-related differentiation in DAC-treated cells. a Bladder tumor cells were treated with DAC every
48 h for 5 days. CK5 protein expression is downregulated in DAC-treated cells on day 5. GAPDH was used as loading control. The western blot is a
representative of triplicate experiments. b Western blots from triplicate experiments were quantitated by ImageJ. CK5 values were normalized to
Tubulin from each condition and plotted on the graph. c CK5 protein expression is downregulated in ICN1 overexpressing cells. GAPDH was used as
loading control. The western blot is a representative of triplicate experiments. d Western blots from triplicate experiments were quantitated by
ImageJ. CK5 values were normalized to Tubulin from control and ICN1 overexpressing cells and plotted on the graph. e The addition of 50ng/ml IL-6
reduced CK5 expression in HT and B02 cells. The addition of a monoclonal antibody against IL-6 rescued CK5 expression only in DAC-treated B02
cells. GAPDH was used as loading control. The western blot is a representative of triplicate experiments. f Western blots from triplicate experiments
were quantitated by ImageJ. CK5 values were normalized to GAPDH from each condition and plotted on the graph.
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NOTCH1, IL-6 and IFN-γ and other related transcripts are
altered in muscle-invasive bladder cancer patients
Our in vitro studies show DAC activation of immune-
related (IL-6 and viral defense) and differentiation-
associated (NOTCH1) transcripts and proteins in blad-
der cancer cell lines. To evaluate if these are clinically
relevant pathways, baseline mRNA levels of these genes
and their methylation status were measured in the MIBC
patients at Roswell Park Cancer Institute and TCGA data
(see materials and methods). NOTCH1, IL-6, and IL-6R
mRNA levels were consistently downregulated in the
TCGA cohort (Fig. 4a). Downstream IL-6 signaling JAK1,
STAT3, and SOCS3 were consistently upregulated in the
same bladder tumors with low IL-6 levels (Fig. 4a) sug-
gesting IL-6 independent activation of the JAK1/STAT3
pathway. STAT1 the intermediate signal in viral defense
pathway was frequently downregulated in bladder tumors
(Fig. 4b). The established signature for the viral defense
mechanism6,7 was also downregulated in MIBC patient
samples (Fig. 4b). In patient samples from RPCI, global
DNA methylation alone can differentiate between adja-
cent non-tumor and tumor bladder tissues (Fig. 5a). Also,
DNA methyltransferase mRNA was upregulated in
tumors compared to non-tumor tissues (Fig. 5b). Pathway
enrichment analysis of differentially methylated genes
revealed that NOTCH belongs to one of the top ten
hypermethylated networks in MIBC patients in the Ros-
well Cohort (Supplementary Table 3). Both NOTCH1 and
IL-6 were downregulated (based on raw counts from RNA
sequencing and z-scores <0) in a subset of RPCI patients
(Fig. 5c, d). Overall, the low levels of NOTCH/IL-6 and
immune-related genes indicate profound dysregulation of
tumor-suppressive pathways in bladder tumors.
Discussion
DNA-demethylating agents reduce proliferation in cell
lines and xenograft models of hematological and solid
malignancies6–8. The mechanism by which that occurs is
not elucidated but studies suggest that cancer cell differ-
entiation8 contributes to the process. It is appreciated that
differentiation of cells with self-renewal potential increa-
ses the sensitivity chemotherapy37,38. This correlates with
the observation that epigenetic therapies sensitize tumors
to chemotherapy treatments10,39,40. DNA-demethylating
agents also alter the immune response by reactivating
cancer testis (CT) antigens41, increasing endogenous ret-
roviruses and repetitive elements7,33, triggering interferon
response thus sensitizing tumors to checkpoint inhibi-
tion6. In this study, we use low non-cytotoxic doses of a
DNA-demethylating agent, Decitabine (DAC), to identify
epigenetically activated pathways in bladder cancer.
We observed for the ﬁrst time that DAC-induced DNA
demethylation upregulated NOTCH1 mRNA in bladder
cancer cells suggesting a functional role for DNA
methylation in the transcriptional regulation of NOTCH1.
We examined 4 and 7 CG dinucleotides in the promoter
and enhancer regions, respectively, and detected sig-
niﬁcant DNA demethylation. Hypomethylation in this
locus appears to be uniform it is important to note that
other sites in these CG-rich regions were not examined
due to technical limitations of PCR ampliﬁcation. The
sites that lay beyond the examined region may not be
Fig. 4 Differentiation-associated transcripts; NOTCH1-IL-6 and viral defense associated transcripts were downregulated in the TCGA
bladder tumor cohort. Normalized mRNA z-scores of TCGA bladder tumor data set revealed downregulation of (a) NOTCH1 and IL-6 transcripts, and
(b). Viral defense transcripts. This downregulation occured independently of p53 expression and metastatic disease. Each row is a gene z-score and
each column is an individual tumor sample. Red color indicates that the gene was expressed at a higher level than the gene with the green color
code within the same tumor.
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methylated contributes to presence of baseline ICN1
protein expression in the control cells. ICN1 expression
despite methylation in NOTCH promoter regions was
also demonstrated by Liu et al.42. In this study, cells with
siRNA against DNMT1 had demethylation of a greater
number of CG sites that enhanced transcription and
ultimately NOTCH1 protein expression compared to cells
with control siRNA42. It is likely that passive demethyla-
tion of the CG-rich promoter region by DAC treatment,
via DNMT1 protein depletion, promotes open chromatin
and allows access of transcriptional machinery at
NOTCH1 locus. It is also possible that factors other than
DNA methylation contribute to regulation of NOTCH1
expression. For example: We did not detect ICN1 protein
in B01 and B02 cells cultured in cholera toxin containing
media possibly due to cholera toxin induced degrada-
tion26. These results suggest that there are additional
post-translational mechanisms that govern NOTCH1
expression. Here, we show for the ﬁrst time that
NOTCH1 expression is induced by low non-cytotoxic
doses of a DNA-demethylating agent. Importantly, epi-
genetic regulation of NOTCH1 expression leads to acti-
vation of downstream effectors that may possess tumor-
suppressive properties in bladder cancer.
NOTCH proteins are structurally conserved with a high
degree of homology between NOTCH1 and NOTCH243,
44. Despite the structural similarity, NOTCH1 exerts tumor
suppressive whereas NOTCH2 exerts oncogenic actions
via different downstream signaling targets in other malig-
nancies45,46. In bladder cancer, NOTCH2 increases cell
Fig. 5 DNA methylation and RNA sequencing data reveal differential methylation and transcript levels in the RPCI cohort. a DNA
methylation of 174 (including 74 matched tumor and non-tumor samples) bladder cancer specimens distinguished between tumor (orange) and
non-tumor tissue (yellow). Red color indicates hypermethylation and green color indicates hypomethylation. Each row is a CG site, and each column
is a different tumor sample. Top 1% differentially methylated CG sites are represented in the heat-map. b–e RNA sequencing was performed on 66
bladder tumor specimens (including 15 matched tumor and non-tumor samples). Transcript levels of DNMT1, CDKN1A, NOTCH1, and IL-6 were
signiﬁcantly lower in tumor tissues as compared to non-tumor tissues.
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proliferation and invasion by regulating EMT genes in vitro
and in vivo47. NOTCH2 copy number gains are frequent in
MIBC patients and correlate with worse overall survival47.
On the other hand, NOTCH1 is lost and expression of its
downstream targets HES-1 and JAGGED-1 are lower in
aggressive MIBC12–14. The function and potentially com-
pensatory or opposing roles of NOTCH proteins have not
yet been well delineated in bladder cancer. For example:
studies show that NOTCH1 is oncogenic and increases cell
proliferation and invasive potential of bladder cancer cells
in vitro48,49. These studies used different approaches to
reduce NOTCH1 expression namely siRNA48 and γ-
Secretase inhibitor49. γ-Secretase is important for not
only cleaving the intracellular domain of NOTCH1 but also
cleaving NOTCH2 to activate NOTCH2 signaling50. It is
possible that using γ-secretase inhibitors will also reduce
NOTCH2 activation. The potential off-target effects of
siRNAs51 and γ-secretase inhibition that affect both
NOTCH1 and NOTCH248,49 expression can account for
the increased cell proliferation and invasive capacity of
bladder cancer cells. In our study, DAC-induced DNA
demethylation of the NOTCH1 promoter and enhancer
regions upregulated NOTCH1 gene transcription with
increase in ICN1 protein, but we are yet to determine the
effects of DAC on NOTCH2 signaling.
We also observed for the ﬁrst time that DAC treatment
and/or NOTCH1 mediated IL-6 release resulted in down-
regulation of CK5 protein expression. Although we attribute
the induction of IL-6 mostly to the NOTCH1 signaling we
suspect, based on previous studies31,32 that increase in
double-stranded mRNA sensors also contributes to IL-6
release in DAC-treated cells. Knockout of individual double-
stranded RNA sensors could potentially conﬁrm this
hypothesis, however other components of this pathway can
functionally compensate for depletion of another compo-
nent. Furthermore, increased IL-6 in DAC-treated B01 and
B02 cells cultured in specialized media occurs without
NOTCH1 activation. This suggests that double-stranded
RNAs can potentially lead to IL-6 release in cells without
NOTCH1 activation. IL-6, a pro-inﬂammatory cytokine,
activates the JAK/STAT pathway mostly associated with
worse prognosis in cancers16,17,52. In bladder cancer, IL-6
through DNMT1 upregulation increases tumorigenic
properties of bladder cancer cells in vitro and in vivo53. In
our studies, DNMT1 protein is depleted by DAC through its
mechanism of action therefore counteracting IL-6 mediated
induction of DNMT1 expression. DAC/NOTCH1 mediated
IL-6 release did not maintain increased phospho-STAT3
levels or cause DNA damage. Our results suggest that in the
absence of DNA damage, DNMT1, and JAK/STAT signal-
ing, IL-6 release most likely plays a role in differentiation, as
observed by reduced CK-5 expression, and elicits anti-tumor
activity in MIBC cells. The tumor-suppressive role of IL-6
may be further clariﬁed by the outcome of an ongoing
clinical trial combining DAC and Ruxolitinib, a JAK/STAT
inhibitor [NCT02076191]. IL-6 is also important in
recruiting immune cells into tumor microenviroment54. It is
possible that DAC and/or NOTCH1 mediated IL-6 release
activates paracrine IL-6 signaling in the microenvironment
to enhance immune cell inﬁltration in MIBC tumors.
The ﬁrst line therapy for patients with locally advanced
and metastatic disease has been cisplatin-based che-
motherapy (CBC). Patients who fail CBC encounter lim-
ited treatment options. Only recently checkpoint based
immune therapies have been approved for treating
patients with metastatic disease55. DNA-demethylating
agents such as DAC can be combined with checkpoint
based immunotherapy to boost the immune system
through increased IFN response6,7. This will provide
additional therapeutic alternatives to CBC for advanced
stage MIBC patients. Another option can be to utilize
DAC-induced molecular pathways to potentiate CBC or
re-sensitize patients to CBC. NOTCH1 upregulation can
increase cisplatin sensitivity based on studies in osteo-
sarcomas15 and in our studies we show that NOTCH1
expression can be induced by a DNA-demethylating
agent. DAC treatment also lowers CK5 protein expression
indicating a reduction in the population of cells with self-
renewing capacity. Increased frequency of cells with self-
renewal capacity is often associated with cisplatin resis-
tance in bladder cancer cells56. Therefore, DAC through
multiple pathways may enhance cisplatin activity in MIBC
patients with no other therapeutic alternatives. DNA
demethylation based epigenetic therapy in combination
with CBC or checkpoint based immune therapy is pro-
mising and should be explored in treatment of MIBC.
Materials and methods
Cell lines, reagents, and treatments
Four bladder cancer cell lines HT1376, T24,
BLCAb00124,25 (B01), and BLCAb00224,25 (B02) were used
in this study. B01 and B02 cells were developed in the Pili
lab24,25. HT1376 cells (ATCC,CRL-1472) were cultured in
MEM (Corning, 10–010CV) with Non-essential amino
acids, T24 cells (ATCC, HTB-4) were cultured in McCoy’s
(Corning, 10–050CV) and B01 and B02 cells were cultured
as speciﬁed in previous studies24,25. Media was supple-
mented with 10% fetal bovine serum, and Penicillin/
Streptomycin and cells were incubated at 37 °C and 5%
CO2 concentration. All the cell lines were tested for
mycoplasma (Lonza, LT07-218) once every 2 months. 1
mM stock concentrations of Decitabine (Sigma, A3656)
was solubilized in aqueous solution and stored at −20 °C
for further use. Decitabine solutions were not thawed more
than once, and 0.1 and 1 µM DAC solutions for cell
treatments were made in media for each cell line. ICN1
plasmid from Addgene (17,623) was transiently transfected
into cell lines using Lipofectamine 3000 (ThermoFisher
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Scientiﬁc, L3000008) and collected at 72 h for further
analysis. IL-6 (Affymetrix, 14-8069-80) was prepared
according to manufacturer’s recommendation and used at
50 ng/ml for up to 7 days. Monoclonal antibody against IL-
6 (Affymetrix, 16-7069-85) was used at a concentration of
1 ng/ml for rescue experiments in DAC-treated cells.
Western blots and qPCR
Cells were plated in 6 well plates and treated with 0.1
and 1 µM DAC every 48 h for up to 5 days. Cells were
collected using RIPA buffer with protease and phospha-
tase inhibitors. Lysates were spun at 16,000× g for 10 min
at 4 °C, and protein concentration in the resulting
supernatant was measured by Bio-Rad DC protein assay
(Bio-Rad, 5000116). 40 µg of total cell lysate was loaded on
Bio-Rad 4–15% gradient gels (567–1084) and was trans-
ferred onto a nitrocellulose membrane followed by
blocking with 5% BSA (Sigma, A9647). The following
primary and secondary antibodies were used in our stu-
dies: DNMT1 (Cell Signaling, 5119), NOTCH1 (Cell
Signaling), p-STAT3 (Cell Signaling, 9145), STAT3 (Cell
Signaling, 4904), CK5 (Covance, PRB-160P), Secondary
Rabbit (GE Biosciences NA934), and Secondary mouse
(GE Biosciences NA931V) at recommended dilutions.
mRNA was isolated using a kit (ZymoResearch, R2052)
followed by cDNA synthesis (Bio-Rad, 170-8891). qPCR
was carried out using SYBR green (Bio-Rad, 172-5121)
and primers for the genes of interest are listed below.
ΔΔCt values were used to calculate fold changes of DAC-
treated cells over control cells
Illumina Inﬁnium 450 K Bead Chip Assay, pyrosequencing,
and Paired-end RNA sequencing
174 bladder tumor samples (including 74 matched non-
tumor and tumors) obtained from patients at Roswell
Park Cancer Institute were analyzed for methylome
changes with the 450 K array. BeadScan in the
GenomeStudio module was used to extract intensities,
summarized by BeadStudio and processed by R. Design
bias was corrected by Swan normalization and loci with
median detection p-value <0.05 were further analyzed. β-
value change of 0.17 was set as the threshold for estab-
lishing the difference between tumor and non-tumor
samples. Pathway enrichment program in Genego was
used to identify the top 10 pathways that contained DAC-
mediated hypomethylated CGs. Network enrichment
program in Genego was similarly used for identifying top
10 gene networks that are hypermethylated in bladder
tumors. For pyrosequencing, DNA was isolated (Qiagen,
51304) and bisulﬁte converted (ZymoResearch, D5031).
The bisulﬁte converted products were ampliﬁed using
PCR primers targeting speciﬁc genes (listed below) and
run on an agarose gel to check for methylation bias.
Pyromark Reagents (Qiagen, 972804), Pyromark Car-
tridge (Qiagen, 979004) and Pyromark plates (Qiagen,
979002) were used for running samples on the pyr-
osequencer. The PCR products were immobilized on
Sepharose beads (GE Healthcare, 17-5113-01), captured
using vacuum, washed with 70% ethanol, denaturation
solution (0.2 M NaOH) and washing buffer (10 mM Tris-
Acetate, pH 7.6). Beads were released in annealing buffer
and heated for 1 min at 80 °C and run on PyroMark Q24
that analyzed percent methylation at each CG site. 1.5 µg
of RNA was used for Paired-end RNA sequencing, and
fastQC was used to check the base quality of the raw
reads. Reads were aligned with Tophat 2 to human gen-
ome b37 from Ensembl. Raw read counts were analyzed
using R, and differentially expressed genes between con-
trol and DAC-treated cells were identiﬁed. Similar RNA
sequencing analysis was performed for 66 bladder tumor
samples (including 15 matched tumor and non-tumor
samples). These were a subset of the samples that were
analyzed for changes in DNA methylation by the 450 K
array. Pathway enrichment program in Genego, available
through Metacore, was used to identify the top 10 path-
ways affected by DAC treatment and altered in bladder
tumor samples. qPCR was used to validate the genes
identiﬁed by Genego in the pathway enrichment analysis.
Gene
name
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β-gal assay and IL-6 ELISA
β-gal positivity was visualized using a colorimetric kit
(Biovision, K320-250). Brieﬂy, cells were washed twice
with PBS, ﬁxed with ﬁxing solution for 10 min, washed
twice with PBS and stained with 2 mg/ml of X-gal over-
night at 37 °C. The next day X-gal solution was replaced
with 70% glycerol and images were taken under bright
ﬁeld microscopy. For IL-6 ELISA, cells were collected by
trypsin, and cell count and viability were measured on a
Vi-Cell automated counter. The cell supernatants were
stored at −80 °C for IL-6 ELISA. IL-6 release in the
supernatants was measured (Affymetrix eBioscience, 88-
7066-22). IL-6 concentrations from absorbance mea-
surements were normalized to cell count, and pg/mL per
106 cells were used to analyze the difference between
DAC-treated or ICN1 overexpression and control cells.
Cell counts, cell viability, and clonogenics
Cells were collected by trypsin and cell counts, and cell
viability were obtained by an automated Vi-cell counter
using trypan blue exclusion method. For clonogenics, cells
were collected on day 3 of DAC treatment, and 50–100
cells were resuspended (depending on the cell line) and
plated in a 12-well plate. Media was refreshed every
3 days, and the clones were collected on day 10 after
plating. The clones were washed and stained with crystal
violet containing 20% methanol for an hour followed by
washing with distilled water and dried overnight. The
numbers of clones were manually counted, and DAC
treatment was compared to control cells.
Flow cytometry and cell size analysis
Cells were collected by trypsin on day 5 of DAC treat-
ment, washed twice with PBS and ﬁxed in 70% ethanol
overnight. Fixed cells were washed twice with PBS, stained
with propidium iodide containing RNase I and were run
on BD Fortessa for cell cycle analysis. FCS express and
forward scatter-width, known to provide an accurate
assessment of cell size,57 was used to calculate relative cell
size differences between control and DAC-treated cells.
Patient data
MIBC patients from Roswell Park Cancer Institute were
collected between the years 1995–2011. Methylation array
(n= 174) and RNA sequencing analysis (n= 66) were
carried out as described before. The TCGA bladder
sample data set for RNA-seq and clinical data were
downloaded (October 2016) and analyzed for the genes of
our interest. There were 412 samples for which RNA-seq,
p53 mutations, and metastatic disease was available and
120 samples for which chemotherapy data was available.
RNA-seq data were normalized using z-scores, and
unsupervised hierarchical clustering was performed to
evaluate correlations between transcript levels, p53
mutations, metastatic disease and chemotherapy
response. A z-score threshold of +1.5 was set for
NOTCH1 and IL-6 up and downregulation in patient
samples. cBioportal was further used to observe survival
differences in genes of our interest58,59. For heatmaps in
Fig. 4 column z-scores were calculated to compare the
levels of gene expression within the same tumor. The
patient demographic for the RPCI data set is presented in
Supplementary Table 3. The patient demographic for the
TCGA data set has been previously published60.
Statistical analysis
GraphPad Prism software was used for plotting graphs
and statistical analysis. Student’s t-test was used to com-
pare DAC treatments with control cells. The time-to-
event outcomes in the RPCI cohort were reported by
NOTCH1 status using standard Kaplan-Meier methods;
with comparisons made using the log-rank test. All ana-
lyses of MIBC patients in the Roswell Park cohort were
conducted in SAS v9.4 (Cary, NC) at a signiﬁcance level of
0.05.
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